Analysts Offer Insights on Healthcare Companies: Pharming Group (OtherPHGUF) and Phreesia (PHR)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2024
0mins
Source: Business Insider
Pharming Group Analysis: RBC Capital maintains a Buy rating on Pharming Group with a price target of EUR1.60, while the analyst consensus suggests a Moderate Buy with an average target of $1.58, indicating a potential upside of 107% from current levels.
Phreesia Rating Update: RBC Capital holds a Hold rating on Phreesia with a price target of $24.00, despite the analyst consensus being a Strong Buy with an average target of $29.75, reflecting differing views on the stock's performance.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is 29.09 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.800
Low
24.00
Averages
29.09
High
35.00
Current: 15.800
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
